CCN2 and idiopathic pulmonary fibrosis: Thus far, the majority of research efforts have been directed towards CCN2/CTGF, but the discontinuation of the phase-3 ZEPHYRUS-1 study of Pamrevlumab for IPF has shifted the spotlight towards other promising CCN members as therapeutic targets.